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MitophagyOmi/HtrA2 is a nuclear encoded mitochondrial serine protease with dual and opposite functions that depend
entirely on its subcellular localization. During apoptosis, Omi/HtrA2 is released into the cytoplasm where it
participates in cell death. While conﬁned in the inter-membrane space of the mitochondria, Omi/HtrA2 has a
pro-survival function thatmay involve the regulation of protein quality control (PQC) andmitochondrial homeo-
stasis. Loss of Omi/HtrA2's protease activity causes the neuromuscular disorder of the mnd2 (motor neuron
degeneration 2) mutant mice. These mice develop multiple defects including neurodegeneration with parkinso-
nian features. Loss of Omi/HtrA2 in non-neuronal tissues has also been shown to cause premature aging. The nor-
mal function of Omi/HtrA2 in the mitochondria and how its deregulation causes neurodegeneration or
premature aging are unknown. Here we report that themitochondrial Mulan E3 ubiquitin ligase is a speciﬁc sub-
strate of Omi/HtrA2. During exposure to H2O2, Omi/HtrA2 degradesMulan, and this regulation is lost in cells that
carry the inactive protease. Furthermore, we show accumulation of Mulan protein in various tissues of mnd2
mice as well as in Omi/HtrA2(−/−) mouse embryonic ﬁbroblasts (MEFs). This causes a signiﬁcant decrease of
mitofusin 2 (Mfn2) protein, and increased mitophagy. Our work describes a new stress-signaling pathway that
is initiated in the mitochondria and involves the regulation of Mulan by Omi/HtrA2 protease. Deregulation of
this pathway, as it occurs in mnd2 mutant mice, causes mitochondrial dysfunction and mitophagy, and could
be responsible for the motor neuron disease and the premature aging phenotype observed in these animals.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
It is now well established that oxidative stress, mitochondrial dys-
function, and deregulation of the ubiquitin–proteasome system (UPS)
underlie selective neuronal cell death and can lead to neurodegenerative
disorders such as Parkinson's disease (PD) [1–3]. Our studies have fo-
cused on the mitochondrial serine protease Omi/HtrA2, originally isolat-
ed in our laboratory, which participates in apoptosis as well as in
mitochondrial homeostasis [4–6]. The role of Omi/HtrA2 in cell death
has been well documented, reviewed in [7–9]. Permeabilization of the
outer mitochondrial membrane upon induction of apoptosis allows the; HtrA2, High temperature re-
ubiquitin–proteasome system;
ne; OMM, mitochondrial mem-
ain; IMD, inter-membrane do-
e; LC3, microtubule-associated
ne; RNF, RING ﬁnger; GAPDH,
thyl sulfoxide
l Sciences, College of Medicine,
rlando, FL 32826, USA. Tel.: +1release of Omi/HtrA2 from the inter-membrane space (IMS) to the cyto-
plasm, where it participates in both caspase-dependent as well as
caspase-independent cell death [10–13]. However, under normal condi-
tions Omi/HtrA2 is restricted to the IMSwhere it performs a pro-survival
function that remains uncharacterized. The notion of a pro-survival role
of Omi/HtrA2 in the IMS arises from the neurodegenerative phenotype of
the Omi/HtrA2 knockout mice that have a targeted deletion of the whole
gene [14]. The same phenotype is also found in the mnd2 mutant mice,
caused by a missense mutation that affects the protease activity of
Omi/HtrA2 [15]. In addition to neurodegeneration, these mutant mice
show a plethora of defects including small size, muscular degeneration,
and atrophy in various organs such as the heart, kidney, thymus, and
spleen [14]. Furthermore, loss of Omi/HtrA2 activity in non-neuronal tis-
sues has recently been shown to cause premature aging [16,17]. In addi-
tion to the effects of Omi/HtrA2 in mouse models, several human studies
linkedOmi/HtrA2 deregulation to neurodegenerative diseases. Pointmu-
tations in Omi/HtrA2 gene have been detected in patients with
Parkinson's disease, andOmi/HtrA2 (PARK13)was identiﬁed as a suscep-
tibility factor for PD [18–20]. Since the protease activity of Omi/HtrA2 is
necessary and essential for its pro-survival function, it suggests that the
cleavage of speciﬁc substrates is involved. Mitochondrial Omi/HtrA2
has been shown to cleave the anti-apoptotic protein Hax-1, Parkin,
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rhomboid-like), and the mitochondrial fusion factor OPA1 [21–26]. Col-
lectively, these reports strongly support the notion that mitochondrial
Omi/HtrA2 has a neuroprotective function.
Here we identiﬁed Mulan (Mitochondrial Ubiquitin Ligase Activator
of NF-kB) [27] also known as GIDE (Growth Inhibition and Death E3
Ligase) [28] or Hades [29], to be a speciﬁc substrate of Omi/HtrA2 prote-
ase. Mulan is localized in the outer mitochondrial membrane (OMM)
and has a domain exposed in the IMS and a RING-ﬁnger domain facing
the cytoplasm [27,28]. We show that Mulan protein levels are tightly
regulated by Omi/HtrA2 protease under normal conditions, during
oxidative stress, or after treatment with the mitochondrial uncoupler
carbonyl cyanide m-chlorophenylhydrazone (CCCP). In addition, we
observed accumulation of the Mulan protein in the tissues of mnd2
mutant mice that lack an active Omi/HtrA2 protease. Furthermore,
we found that upregulation of Mulan, in the absence of Omi/HtrA2,
leads to the degradation and removal of Mfn2 protein. Mfn2 down-
regulation by Mulan ligase has previously been shown to induce
mitochondrial dysfunction and mitophagy in muscle cells [30,31]. Our
studies clearly show that the absence of Omi/HtrA2 protease leads to in-
creased mitophagy in MEFs under normal conditions or after treatment
with CCCP. This is the ﬁrst report of a direct link betweenmitochondrial
Omi/HtrA2, Mulan E3 ubiquitin ligase and mitophagy. This mechanism
deﬁnes a new function of Omi/HtrA2 in mitochondrial homeostasis.
Furthermore, it suggests how the absence of Omi/HtrA2 or its inactiva-
tion can lead to mitochondrial dysfunction and mitophagy, resulting in
neuronal cell death, premature aging, and the overall phenotype ob-
served in the mnd2 mutant mice.
2. Materials and methods
2.1. Cell culture
HEK293 and HK-2 (human kidney-2: renal proximal tubular epithe-
lial cells) were obtained from ATCC, and cultured in DMEM containing
10% fetal bovine serum, 50 units/ml of penicillin and 50 μg/ml of strep-
tomycin [22]. Omi/HtrA2 mouse embryonic ﬁbroblasts (MEFs) were
derived from Omi/HtrA2 knockout mice [14]. Omi/HtrA2(−/−),
Omi/HtrA2(+/+) and Omi/HtrA2-S/A MEFs were generated by stably
transfecting the MSCV vector alone (−/−), MSCV-Omi/HtrA2(+/+)
or MSCV-Omi/HtrA2-S/A (Ser306Ala). All three cell lines were main-
tained in Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented
with 10% fetal bovine serum, 50 units/ml of penicillin, 50 μg/ml
of streptomycin and 0.5 μg/ml of puromycin. Oxidative stress was
induced using 50 μM of H2O2 for 10 h. These conditions have been
previously shown to induce optimal stress in Omi/HtrA2(−/−) and
Omi/HtrA2(+/+) MEFs [14,25].
2.2. Antibodies, chemicals and Western blot analysis
Antibodies used in our study include: Mulan polyclonal (Novus
Biologicals), Omi/HtrA2 rabbit polyclonal [22,32], March5 polyclonal
(Aviva Systems Biology), RNF185 polyclonal (Genetex), cytochrome c
monoclonal (R&D Systems),Mfn2monoclonal (Santa Cruz Biotechnolo-
gy), GAPDH and β-actin monoclonal antibodies (Sigma). Secondary
peroxidase-conjugated goat anti-rabbit, goat anti-mouse or donkey
anti-goat antibodies were from Jackson ImmunoResearch Laboratories.
Non-potentiometric MitoTracker Red 580 and MitoTracker Green
were used as recommended [33]. MitoTracker dyes, MitoSOX, and
LysoTracker Red were fromMolecular Probe. H2O2, etoposide, cisplatin,
antimycin, paraquat and CCCP were all purchased from Sigma. Control
cells, as well as cells treated with H2O2, were lysed using a Triton
X-100 based lysis buffer (1% Triton X-100, 10% glycerol, 150 mM NaCl,
20 mM Tris (pH 7.5), 2 mM EDTA) in the presence of a protease inhib-
itormix (Roche Applied Science). Approximately 20 μg of whole cell ex-
tract was mixed with 2× SDS-sample buffer and boiled for 5 min. Thesamples were resolved on SDS-PAGE and electro-transferred onto
polyvinylidene diﬂuoride (PVDF) membranes (Thermo Scientiﬁc)
using a semi-dry cell transfer blot (Bio-Rad). 4% nonfat dry milk in
TBST buffer (25 mM Tris–HCl, pH 8.0, 125 mM NaCl, 0.1% Tween 20)
was used to block nonspeciﬁc binding of themembrane. Themembrane
was incubated with the indicated primary antibodies followed by the
speciﬁc secondary peroxidase-conjugated antibodies. The membrane
was visualized by enhanced chemiluminescence (ECL) (Thermo
Scientiﬁc).2.3. Subcellular fractionation and apoptotic assay
HK-2 (human kidney 2) cells were grown in 150 mm dishes. When
the cells reached 90% conﬂuence, they were treated with H2O2 (200
μM) or etoposide (125 μM) for 10 h. After this time, the cells were de-
tached using trypsin–EDTA (Invitrogen), washed twice with ice-cold
phosphate-buffered saline and processed for fractionation using the
commercially available Mitochondria Isolation Kit (Thermo Scientiﬁc)
according to the manufacturer's instructions. Brieﬂy, the homogenized
cells were centrifuged at 700 ×g for 10 min and the pellet representing
the crude nuclear fractionwas discarded. The supernatantwas collected
and centrifuged at 3000 ×g for 15 min. Both the resultant pellet,
representing the mitochondrial fraction, and the supernatant cytosolic
fractions were collected. The fractions were analyzed by SDS-PAGE
and Western blot using the following antibodies: Mulan, Omi/HtrA2,
cytochrome c, and β-actin. A fraction of the treated cells was used for
cell death assay; the cells were resuspended in 1× binding buffer and
stained with Annexin V and 7-AAD according to BD Biosciences proto-
col, followed by analysis on a FACSCalibur ﬂow cytometer. Cell death
in the population was estimated using Annexin V (early apoptosis)
and 7-aminoactinomycin D (late apoptosis) [22,34,35].2.4. In vitro degradation assay
The ability of recombinant His-Omi134–458 protease to cleave Mulan
in vitro was investigated. For this experiment, the inter-membrane
domain (IMD) of the Mulan protein corresponding to amino acids
30–240 (His-Mulan30–240) and the cytoplasmic domain (CD) corre-
sponding to amino acids 245–352 (His-Mulan245–352) were cloned in
frame in the pET-28a bacteria expression vector (Novagen). Recombi-
nant proteins His-Mulan30–240 and His-Mulan245–352 were puriﬁed on
nickel-nitrilotriacetic acid (Ni-NTA) afﬁnity resin as previously de-
scribed [36]. His-Omi134–458 (400 ng) or His-Omi-S/A134–458 (encoding
the inactive protease) was incubated with 400 ng of His-Mulan30–240
or His-Mulan245–352 in 15 μl reaction volume in the assay buffer
(20 mM Na2HPO4 (pH 8), 10% glycerol, 200 mM NaCl). After 20, 40,
and 60 min of incubation at 37 °C, the reactions were stopped with
the addition of 2× SDS-sample buffer. Reaction products were analyzed
by SDS-PAGE followed by Coomassie Blue staining.2.5. Expression of Mulan and Omi/HtrA2 proteins in various tissues derived
from mnd2 mutant mice
Mouse tissues were prepared as described [36]. In short, tissue sam-
ples were taken from 25-day old mnd2 mutant mice as well as their
wild type littermates and immediately placed in ice-cold lysis buffer
containing 150 mM NaCl, 20 mM Tris·HCl, pH 7.6, 1 mM CaCl2, 1 mM
MgCl2, 10% glycerol, 1% Nonidet P-40, 5 mM NEM (N-Ethylmaleimide),
and complete protease mixture tablets (Roche). Tissues were homoge-
nized with an Ultra-Turrax T8 (IKA-werke). Protein concentration was
determined using the Bio-Rad protein assay. Approximately 20–50 μg
of whole cell extract was used for SDS-PAGE followed by Western blot
analysis.
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with various stress-inducing chemicals
HK-2 cells were grown in six-well plates in the appropriate media
until they reached 80% conﬂuence; they were then treated for 10 h
with one of the following: cisplatin (40 μM), etoposide (125 μM),
H2O2 (200 μM), antimycin (10 μM), or antimycin (10 μM). Cells were
also treated with Paraquat (300 μM) for 12 h. After this time, cells
were detached, washed twice with ice-cold phosphate-buffered saline
(PBS), and re-suspended in lysis buffer for Western blot analysis. Mea-
surement of mitochondrial reactive oxygen species (ROS) and cell
death was assessed as previously described [32,37,38]. Brieﬂy, after
the various treatments cells were detached by trypsinization, washed,
and stained either for 30 min at 37 °C with 5 μM of MitoSOX red or
with Annexin V and 7-AAD for 20 min at room temperature. After this
time cells were washed twice with HBSS and analyzed by FACScalibur.
2.7. Ectopic expression of Omi-GFP or Omi-S/A-GFP
HEK293 (human embryonic kidney) cell line was used for transfec-
tion experiments. Cells were grown in six-well plates and transfected
with GFP-N1, Omi-GFP, or Omi-S/A-GFP (encodes the inactive protease)A 
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Fig. 1. Regulation ofmitochondrial Mulan E3 ligase by Omi/HtrA2 protease. (A)Mitochondria h
in the outer mitochondrial membrane and have their RING-ﬁnger domain exposed to the cytop
chondrial membrane (OMM), inner mitochondrial membrane (IMM), inter-membrane space (
blot analysis of Mulan,March5 and RNF185 protein expression in Omi/HtrA2(−/−) and Omi/H
Omi/HtrA2(−/−) and Omi/HtrA2(+/+) MEFs; (C) Omi/HtrA2(−/−), Omi/HtrA2(+/+) and
prepared as described in Materials and methods. The protein level of Mulan was monitored
Omi/HtrA2-S/A MEFs; β-actin antibody was used to verify equal loading in each lane. The grap
with 125 μM of etoposide or 200 μMH2O2 for 10 h and mitochondrial and cytoplasmic fraction
weremonitored byWestern blot analysis. Cytochrome c and β-actinwere used as controls. (E) P
(early apoptosis) or 7-aminoactinomycin D (late apoptosis) staining and analyzed by ﬂow cyto
#P b 0.05 versus control.plasmids using Lipofectamine 2000 (Invitrogen). Eighteen hours after
transfection, cells were treated with etoposide (125 μM) or with H2O2
(200 μM) for 10 h. Cell extractswere prepared and analyzed byWestern
blot using speciﬁc antibodies.
2.8. Relative abundance of mitochondria in Omi/HtrA2(−/−),
Omi/HtrA2(+/+), and Omi-S/A MEFs
The relative abundance of mitochondria in Omi/HtrA2(−/−),
Omi/HtrA2(+/+), and Omi-S/A MEFs was monitored as previously de-
scribed [39,40]. Brieﬂy, equal numbers of MEFs were grown in 12-well
plates for 12 h and then washed with PBS, trypsinized, re-suspended
in the appropriate buffer and stained with MitoTracker Red 580
(100 nM; Molecular Probes) for 30 min at 37 °C. The cells were then
washed and analyzed by FACSCalibur (BD Biosciences). CellQuest anal-
ysis software (BD Biosciences) was used for data analysis.
2.9. Confocal microscopy
Equal numbers of Omi/HtrA2(+/+) and (−/−) MEFs were seeded
on glass coverslips in 12-well plates. Twelve hours later they were
placed in a medium containing GFP-LC3 adenovirus (kindly providedinV 7-AAD 
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ave three distinct E3 ubiquitin ligases: Mulan,March5, and RNF185. They are all embedded
lasm [27,28,47,49]. RING-ﬁnger domain (RNF), Transmembrane (TM), outer mito-
IMS). Under normal conditions, Omi/HtrA2 is present exclusively in the IMS. (B) Western
trA2(+/+)MEFs grown under normal conditions. The graph showsMulan/β-actin ratio in
Omi/HtrA2-S/A MEFs were treated with 50 μM H2O2 for 10 h and total cell extracts were
by Western blot analysis. Omi/HtrA2 is present in the Omi/HtrA2(+/+) as well as in
h shows the Mulan/β-actin ratio after densitometry analysis; (D) HK-2 cells were treated
s were prepared. The sub-cellular localization and protein levels of Mulan and Omi/HtrA2
ercentage of cell death after H2O2 or etoposide treatmentwasmonitored using Annexin V
metry. All results shown in this ﬁgure are means± S.D. of three independent experiments
1298 L. Cilenti et al. / Biochimica et Biophysica Acta 1843 (2014) 1295–1307by Dr. Gustafsson) [41–43]. After 24 h of incubation, cells were loaded
with MitoTracker Red and treated with CCCP (20 μM) or DMSO control
for 4 h. Cells were washed, ﬁxed with 4% paraformaldehyde for 15 min
andmounted in a glass slide. Cells were examined using a LSM710 con-
focal microscope, and analyzed using ZEN lite software (Carl Zeiss). To
assess the degree of autophagy, GFP-LC3 ﬂuorescence was examined
at 63× magniﬁcation and cells were classiﬁed as having diffuse GFP-
LC3 ﬂuorescence or as cells with N10GFP-LC3 puncta/cell. For the quan-
tiﬁcation of autophagosomes in single cells, at least 50 representative
cells per condition in three separate experiments were acquired, and
the number of autophagosomes in each cell was counted. In addition,
we used LysoTracker Red (LTR) andMitoTracker Green (MTG) to assess
mitophagy, where depolarized mitochondria co-localize with auto-
phagosomes. LTR is an acidotropic ﬂuorescent probe used to label and
track acidic organelles in living cells including lysosomes and auto-
phagosomes [44–46]. Omi/HtrA2(+/+) and Omi/HtrA2(−/−) MEFs
were treated with 20 μM CCCP or DMSO (control) and loaded with
LTR (200 mM) and MTG (200 nM) for 2 h. Cells were washed, ﬁxed
with 4% paraformaldehyde and mounted in a glass slide. Confocal mi-
croscopy was used to monitor ﬂuorescence which was examined at
100× magniﬁcation.
2.10. Statistical analysis
All quantitative data is expressed asmean±SDof three or ﬁve inde-
pendent experiments. Following Western blot analysis, Mulan/GAPDH
or Mulan/β-actin ratios were obtained from the densitometry dataA 
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Fig. 2.His-Omi/HtrA2134–458 can degrade the inter-membrane domain of Mulan (His-Mulan30–
transmembrane domains ( TM), the inter-membrane domain (IMD) used in this experimen
cytoplasm. (B) Recombinant, puriﬁed His-Mulan30–240 (IMD) was incubated with His-Omi134–4
HtrA2-S/A134–458 proteasewas also usedwith His-Mulan30–240 for the same time periods. (D) Th
same assay. His-Mulan245–352 was incubatedwith His-Omi134–458 for 40 and 60min. No degrad
was veriﬁed using the generic substrate β-casein. All reactions were resolved on SDS-PAGE, anusing a Bio-Rad Chemidoc XRS imaging system and analyzed by
Quantity One software. Differences among groups were analyzed by
one-way ANOVA followed by Tukey–Kramer method using StatPlus
software. A value of P b 0.05 was considered signiﬁcant.
3. Results
3.1. Omi/HtrA2 protease regulates the protein levels ofMulan under normal
conditions as well as in response to oxidative stress
Omi/HtrA2 is a serine protease that under normal conditions is pres-
ent exclusively in the IMS of the mitochondria. Mulan E3 ubiquitin li-
gase is anchored in the OMM. It has two trans-membrane regions
separated by 210 amino acids that create a large IMS domain (Fig. 1A).
Furthermore, Mulan's RING-ﬁnger domain facing the cytosol has exten-
sive amino acid similarity to the corresponding domain of the Inhibitor
of Apoptosis Proteins (IAPs), which are known substrates of the
Omi/HtrA2 protease; however, the biological signiﬁcance of this homol-
ogy is unclear [28]. March5 and RNF185 are transmembrane proteins
that cross the OMM four and two times, respectively. They are the
only other two known mitochondrial E3 ubiquitin ligases that have
their RING-ﬁnger domain exposed to the cytoplasm (Fig. 1A)
[27,28,47–49]. We determined the protein levels of Mulan, March5,
and RNF185 in whole cell lysates prepared from Omi/HtrA2(−/−) as
well as Omi/HtrA2(+/+) MEFs. While no signiﬁcant difference was
observed in the level of March5 or RNF185, a substantial increase in
Mulan protein level was observed in Omi/HtrA2(−/−) compared to9                      302            340     
352 RNF 
pET28-MULAN245-352 
CD 
His-Mulan30-240
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240) in vitro. (A) Schematic diagram ofMulan protein indicating the relative location of the
t, as well as the RING-ﬁnger ( RNF) domain and cytoplasmic domain (CD) that faces the
58 at 37 °C for various time periods (20, 40, 60 min). (C) For control, the inactive His-Omi/
e CD ofMulan, corresponding to the aa245–352 (His-Mulan245–352), was also tested in the
ation of His-Mulan245–352 was observed. The proteolytic activity of the His-Omi134–458 used
d the gels were stained with Coomassie Blue.
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be a potential substrate of Omi/HtrA2.
We further investigated whether the proteolytic activity of
Omi/HtrA2 is required forMulan regulation especially under conditions
of oxidative stress. For these experiments, we used Omi/HtrA2(−/−)
MEF as well as Omi/HtrA2(−/−) MEF cells where Omi/HtrA2 activity
has been rescued by stable transfection of Omi/HtrA2 wild type gene,
Omi/HtrA2(+/+), or an Omi/HtrA2 mutant form Omi/HtrA2-S/A.
Omi/HtrA2-S/A carries an amino acid substitution (Ser306Ala) that
completely abolishes the proteolytic activity of the enzyme [10].
Fig. 1C shows that the basic expression of Mulan protein was much
higher in Omi/HtrA2(−/−) and Omi/HtrA2-S/A compared to that in
Omi/HtrA2(+/+)MEFs. In addition, treatmentwith hydrogen peroxide
(H2O2) resulted in a notable reduction of Mulan protein level in Omi/
HtrA2(+/+) MEFs. However, in Omi/HtrA2(−/−) or Omi/HtrA2-S/A
MEFs, H2O2 had no detectable effect (Fig. 1C). These results indicate
that the down-regulation of Mulan protein by oxidative stress requires
the presence of an active Omi/HtrA2 protease. The same blot was also
probed for Omi/HtrA2 protein expression in the three cell lines used.
As expected, in the Omi/HtrA2(−/−) MEFs there is complete absence
of Omi/HtrA2 protein expression, and H2O2 treatment did not affect
the levels of wild type or Omi/HtrA2-S/A protein in the corresponding
cell lines.
Next, we tested whether the cleavage and the degradation of Mulan
following H2O2 treatment occur in the mitochondria or the cytoplasm.
Since H2O2 induces cell death, we investigated whether cleavage of
Mulan is a result of the pro-apoptotic function of Omi/HtrA2 in the cyto-
plasm. For this experiment, cells were treated with H2O2 or etoposide.
Mitochondrial and cytoplasmic fractionswere prepared, and theprotein
levels of Mulan and Omi/HtrA2 were analyzed by SDS-PAGE andWest-
ern blot using speciﬁc antibodies. Cytochrome c and β-actin were also
used as controls. Fig. 1D shows that Mulan is exclusively present in
the mitochondria, and its protein level was signiﬁcantly reduced after
the cells were treated with H2O2, whereas etoposide treatment had no
detectable effect. Under these conditions, H2O2 and etoposide treat-
ments induced about 40% apoptosis in the cell population (Fig. 1E),0 
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independent experiments (n = 3 for each tissue).and both caused the release of Omi/HtrA2 and cytochrome c into the cy-
toplasm. These experiments suggest that the speciﬁc degradation of
Mulan protein during H2O2 treatment occurs while Omi/HtrA2 is con-
ﬁned in the mitochondria and is not part of the pro-apoptotic pathway.
The small amount of Omi/HtrA2 proteins present in the cytoplasm of
control (untreated) cells is due to a slight cross contamination between
these two fractions.
3.2. Mulan30–240 is cleaved by Omi/HtrA2 protease in vitro
We testedwhetherMulan protein could be a substrate of Omi/HtrA2
protease in vitro and, if so, to identify which domain of Mulan, inter-
membrane domain (IMD) and/or cytoplasmic domain (CD), is cleaved.
For this experiment, the IMD of Mulan (Fig. 2A) corresponding to
amino acids 30–240 (His-Mulan30–240), as well as Mulan CD, amino
acids 245–352 (His-Mulan245–352) were cloned, expressed in bacteria,
and puriﬁed as described in the Materials and methods section. His-
Mulan30–240 was incubated with His-Omi/HtrA2134–458 protease for dif-
ferent time periods. Fig. 2B shows thatHis-Omi/HtrA2134–458was able to
degrade the Mulan30–240 IMD in this assay. To verify if the cleavage of
Mulan30–240 was due to Omi/HtrA2 activity and not to some other con-
taminating bacterial protease, we used an inactive His-Omi/HtrA2-S/
A134–458 protease. This enzyme has the Serine 306 replaced with an Ala-
nine, which completely abolishes its protease activity [10,11]. When
used in this assay, His-Omi/HtrA2-S/A134–458 was not able to degrade
His-Mulan30–240 (Fig. 2C). When the CD His-Mulan245–352 was tested
in the same in vitro assay, it was not cleaved by His-Omi/HtrA2134–458
(Fig. 2D). The activity of the recombinant His-Omi/HtrA2134–458 prote-
ase was veriﬁed using β-casein as a generic substrate (Fig. 2D).
3.3. Expression ofMulan andOmi/HtrA2 proteins in various tissues ofmnd2
mutant mice
Mnd2mutant mice carry a single missense mutation (Ser276Cys) in
the Omi/HtrA2 gene [15]. This mutation inactivates the protease activity
of Omi/HtrA2. Fig. 3A shows the protein level ofMulan in various tissueseart                                      Kidney                     Spleen          
/+     -/-    -/-     -/-          +/+   +/+   -/-   -/-    +/+   +/+    -/-   -/-     
e extracts were prepared from the brain (striatum and cortex), heart, kidney, or spleen of
e analyzed for Mulan and Omi/HtrA2 protein expression using Western blot with speciﬁc
Mulan/GAPDH ratio after densitometry analysis; results shown are means± S.D. of three
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protein levels are substantially higher in the heart, spleen, and kidney
tissues, as well as in the cortex and the striatum of mnd2 mice that do
not have a functional Omi/HtrA2 protease. All of these organs from
mnd2 mutant mice show clear morphological defects. Furthermore,
excessive neuronal cell death in the striatum has been implicated
in the neurodegenerative disorder and the early death of these mutant
animals [15].
3.4. Regulation of Mulan, Omi/HtrA2, and Mfn2 proteins in HK-2 cells
treated with various stress-inducing chemicals
HK-2 cells were treated with various chemicals including: cisplatin,
etoposide, H2O2, antimycin and paraquat. Fig. 4A clearly shows thatA 
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Fig. 4.Regulation ofMulan,Omi/HtrA2 andMfn2protein levels by various chemical stressors an
cisplatin (40 μM), etoposide (125 μM), H2O2 (200 μM), antimycin (10 μM)or paraquat (300 μM)
andWestern blot. Expression of β-actin was used to verify equal loading in each lane. (B) Perc
(early apoptosis) or 7-aminoactinomycin D (late apoptosis) staining was used and the cells we
periments #P b 0.05 versus control. (C) Mitochondrial ROS production in HK-2 cells treated w
stained for 30minwith 5 μMofMitoSOX and analyzed by FACSCalibur. Results shown aremean
with H2O2 (200 μM) for various times. Expression ofMulan and Omi/HtrA2 proteins, at each tim
equal loading in each lane. (E) Percentage of cell death in HK-2 cells treatedwith H2O2 (200 μM
staining was used and the cells were analyzed by ﬂow cytometry. Results shown are means ±
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the endogenous Omi/HtrA2 since it carries an epitope tag. Lower graph depicts the Mulan/β-ac
experiments.H2O2 is the only treatment able to induce signiﬁcant reduction in
Mulan protein level under these conditions. There was no detectable
change in the protein level of Omi/HtrA2 under any of these conditions
(Fig. 4A). We also monitored the level of Mfn2 protein, a known sub-
strate of Mulan, and a protein involved in mitochondrial fusion. As ex-
pected there is an inverse correlation between the protein levels of
Mulan andMfn2. To verify that the chemical treatmentswere detrimen-
tal to the cells, wemonitored the percentage of cell death for each treat-
ment (Fig. 4B) as well as the relative amount of mitochondrial ROS
(reactive oxygen species) produced using MitoSOX staining (Fig. 4C).
H2O2, antimycin and paraquat produced the highest levels of ROS and
cell death (Fig. 4A and B). A time course of Mulan degradation following
treatmentwithH2O2 is shown in Fig. 4D.Mulandegradationwas detect-
able after 8 h and there was no change in Omi/HtrA2 protein levelscon      4        8        10     14  
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1301L. Cilenti et al. / Biochimica et Biophysica Acta 1843 (2014) 1295–1307throughout the time period of the experiment. Fig. 4E shows the per-
centage of apoptotic cells in the population over the 14 h period.
3.5. Effect of Omi-GFP or Omi-S/A-GFP overexpression on endogenous
Mulan protein levels
We investigated whether overexpression of Omi/HtrA2 in HEK293
cells will affect the protein levels of Mulan further supporting the idea
that Mulan is a physiological substrate of Omi/HtrA2 in vivo. For these O
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# 
Fig. 5. Relative abundance of mitochondria in the presence of Omi/HtrA2 and regulation of Mu
MEFs were grown in twelve-well plates for 12 h. After this time cells were loaded with 200 nM
intensity histogram followingmitochondrial staining in the three cell lines. Results shown are a
(B) Cell lysates prepared fromOmi/HtrA2(−/−), Omi/HtrA2(+/+), andOmi/HtrA2-S/AMEFs t
and Omi/HtrA2 speciﬁc antibodies. Graph shows the Mulan/β-actin ratio after densitometry anexperiments, we transfected HEK293 cells with Omi-GFP or the inactive
formOmi-S/A-GFP. Omi-GFP is processed by auto-cleavage to formma-
ture Omi (aa134–458). This form of Omi/HtrA2 runs a little bit higher
than the endogenous Omi/HtrA2 due to the presence of an epitope
tag. The inactive protease Omi-S/A-GFP cannot be processed by auto-
cleavage to form the mature Omi/HtrA2. Fig. 4F shows that cells
transfected with Omi-GFP and treated with H2O2 show signiﬁcant
Mulan degradation due to the increased protein level of Omi/HtrA2. In
contrast, over-expression of the inactive form of Omi-S/A-GFP had no
effect and competed with the endogenous Omi/HtrA2 protease to par-
tially block Mulan degradation. All these data indicate that Omi/HtrA2
is solely responsible for regulating Mulan protein levels. HEK293 cells
were used for this transfection experiments since, unlike HK-2 or
MEFs, they can be transfectedwith very high efﬁciency. Etoposide treat-
ment has no effect on Mulan protein levels and was used here as a neg-
ative control.
3.6. Assessment of the mitochondria abundance in Omi/HtrA2(−/−),
Omi/HtrA2(+/+), and Omi-S/A MEFs and regulation of Mulan by
CCCP treatment
Mulan E3 ligase has been previously shown to be involved in
mitophagy [30]. Mitochondrial dysfunction and increased autophagy/
mitophagy have also been reported in the absence of Omi/HtrA2 prote-
ase activity [17].We investigated the relative abundance of healthymito-
chondria present in Omi/HtrA2(−/−) compared to Omi/HtrA2(+/+)
or Omi/HtrA2-S/A MEFs. For these experiments, MEFs were stained
with MitoTracker Red and analyzed by ﬂow cytometry. The histogram
in Fig. 5A shows that Omi/HtrA2(+/+) MEFs have more healthy mito-
chondria as seen by the higher intensity of MitoTracker-Red staining
compared to Omi/HtrA2(−/−) or Omi/HtrA2-S/A MEFs. Furthermore,
we investigated if Mulan protein levels were affected differently by
CCCP treatment in the absence of Omi/HtrA2 protease. CCCP is a mito-
chondrial uncoupler and an inducer of mitophagy [50]. For these exper-
iments, Omi/HtrA2(−/−), Omi/HtrA2(+/+), and Omi/HtrA2-S/A MEFs
were treated with CCCP, and the Mulan protein levels were analyzed by
Western blotting. Fig. 5B shows that CCCP treatment increases theB Om
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1302 L. Cilenti et al. / Biochimica et Biophysica Acta 1843 (2014) 1295–1307protein level of Mulan in all three cell-lines. However, there is signiﬁ-
cantly more accumulation of Mulan protein in the two MEFs that either
lack Omi/HtrA2 or have the inactive Omi/HtrA2-S/A protease. These re-
sults show a clear correlation between the absence of Omi/HtrA2 prote-
ase and accumulation of Mulan following CCCP treatment, and are
consistent with our hypothesis that high levels of Mulan protein invari-
ably lead to increased mitophagy.
3.7. Assessment of mitophagy in Omi/HtrA2(+/+) and Omi/HtrA2(−/−)
MEFs using confocal microscopy
We compared the degree of mitophagy between the Omi/
HtrA2(+/+) and Omi/HtrA2(−/−) MEFs following treatment with
the mitochondrial uncoupler CCCP [50–53]. For these experiments,
cells were infected with GFP-LC3 expressing adenovirus, treated with
CCCP, and loadedwithMitoTracker Red 580 that accumulates in the mi-
tochondria with an intact membrane potential. In the absence of CCCP
treatment, GFP-LC3 is diffusely distributed throughout the cytoplasm
in both Omi/HtrA2(+/+) and Omi/HtrA2(−/−) MEFs (Fig. 6A top
panels). After CCCP treatment, a large number of GFP-LC3-positiveO
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Fig. 6.Mitophagy in Omi/HtrA2(+/+) and (−/−) MEFs following CCCP treatment. MEFs were
with 20 μMof CCCP or DMSO as control for 4 h. (A) A single representative image ofMEF cells sh
images of the two. Treatment with CCCP induced numerous GFP-LC3 puncta positive cells in O
puncta (Green) with red-labeled mitochondria. Image contrast and brightness was adjusted
counting the number of GFP-LC3 puncta per cell containing N10 GFP-LC3 puncta positive cell fr
ences in numbers of GFP-LC3 puncta positive in Omi/HtrA2(−/−) compared with Omi/HtrA2(
experiments #P b 0.05 versus Omi(+/+).aggregates (autophagosomes) appear in the Omi/HtrA2(−/−) cells
compared to only a few present in the Omi/HtrA2(+/+) MEFs
(Fig. 6A). Many of these GFP-LC3-positive autophagosomes co-localize
with red ﬂuorescence-labeled mitochondria (yellow dots indicated
by arrows). For a more quantitative analysis of the mitophagy in Omi/
HtrA2(+/+) and Omi/HtrA2(−/−) MEFs, random images of cells with
or without CCCP treatment were captured and analyzed. A minimum
of 50 cells per condition per experiment were analyzed and classiﬁed
as: (a) cells with diffuse GFP-LC3 ﬂuorescence (untreated/control), or
as (b) cells with numerous GFP-LC3 puncta (N10dots/cell) representing
autophagosomes. Omi/HtrA2(+/+) MEFs show signiﬁcantly less
GFP-LC3 puncta compared to the Omi/HtrA2(−/−) MEFs (Fig. 6B).
3.8. Assessment of autophagosomes and co-localization with depolarized
mitochondria in Omi/HtrA2(+/+) and Omi/HtrA2(−/−) MEFs
Weused LysoTracker Red (LTR) andMitoTracker Green (MTG) to ob-
serve late mitophagy, where depolarized mitochondria are sequestered
into autophagosomes. LTR is an acidotropic ﬂuorescent probe used to
label and track acidic organelles in living cells including lysosomes and0 
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owing the subcellular distribution of GFP-LC3 (green), MitoTracker-Red (red) andmerged
mi/HtrA2(−/−) and fewer in Omi/HtrA2(+/+) cells. Arrows indicate GFP-LC3-positive
using Adobe Photoshop. (B) Quantiﬁcation was assessed by imaging random ﬁelds and
om three independent experiments following CCCP or DMSO (control) treatments. Differ-
+/+) were statistically signiﬁcant. Results shown are means ± S.D. of three independent
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MEFswere treatedwith 20 μMCCCP or DMSO (control) for 4 h and load-
ed with LTR andMTG for 2 h. Confocal microscopy was used to examine
cells. Fig. 7A shows that Omi/HtrA2(−/−) MEFs have more LTR-labeled
organelles per cell compared to Omi/HtrA2(+/+) cells. This difference
becomes even more pronounced after CCCP treatment. There is also ex-
tensive co-localization of MTG-stained mitochondria and LTR-stained
autophagosomes (yellow spots). Omi/HtrA2(+/+) MEFs show signiﬁ-
cantly less LTR puncta per cell compared to the Omi/HtrA2(−/−)
MEFs (Fig. 7B).
3.9. Deregulation of Mulan affects the protein level of Mfn2 protein in the
heart of mnd2 mutant mice
We investigated whether the up-regulation of Mulan that is ob-
served in the absence of Omi/HtrA2 protease directly affects its down-
stream targets. There are several known substrates of Mulan E3
ubiquitin ligase including NF-κΒ, JNK, p53, Akt, and Mfn2 [28–30,54].
In terms of mitochondrial function, the most relevant substrate is the
Mfn2, a protein involved inmitochondrial fusion that is down-regulated
during mitophagy [55,56]. Mfn2 is ubiquitinated by Mulan and isO
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Fig. 7. Assessment and co-localization of autophagosomes with depolarized mitochondria in O
DMSO (control) for 4 h. LysoTracker Red (LTR) and MitoTracker Green (MTG) were used to s
(DMSO) and CCCP treated MEF cells showing the subcellular distribution of MTG (green), LTR
ﬁelds from three independent experiments determining the number of LTR-labeled organelles
numbers of LTR-ﬂuorescence in Omi/HtrA2(−/−) compared with Omi/HtrA2(+/+) was stat
This MTG-LTR co-localization becomes more prominent after CCCP treatment and is substa
means ± S.D. of three independent experiments #P b 0.05 versus Omi/HtrA2(+/+).targeted for proteasome-induced degradation [30]. Furthermore, it has
been previously shown that Mfn2 is regulated by Mulan in the skeletal
muscles and also plays an important role in the heart [30]. We investi-
gated whether the Mulan deregulation that occurs in the absence of
Omi/HtrA2 can affect Mfn2 protein. We used heart tissues where
Mfn2 protein is fairly abundant and easily detected. Fig. 8A shows the
respective protein levels of Mulan and Mfn2 in heart tissues derived
from mnd2 mutant mice (−/−) as well as their wild type littermates
(+/+). There is an inverse correlation between the protein levels of
Mulan and Mfn2. Mnd2 mutant mice have higher levels of Mulan
protein (also shown in Fig. 3A) but signiﬁcantly reduced levels of
Mfn2 protein compared to the protein levels of the wild type animals.
The Omi/HtrA2 protein levels are very similar, although the mnd2 mu-
tant animals carry the mutated form of the gene (Ser276Cys) that lacks
detectable proteolytic activity.
4. Discussion
Most studies about Omi/HtrA2 have focused on its role as a pro-
apoptotic protein when it is released from the mitochondria during ap-
optosis, but themain function of Omi/HtrA2 within the mitochondria is           Merge 
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Fig. 8.Deregulation ofMulan affectsMfn2protein levels in the heart ofmnd2mutantmice. (A)Mouse tissue lysateswere prepared from thehearts of 25-day oldmnd2(−/−)mutantmice
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[6,16,17,57–59]. A pro-survival role for Omi/HtrA2 in the mitochondria
is supported by the link between the loss of Omi/HtrA2 and neurode-
generative diseases. The mnd2 mutant mice have lost the activity of
Omi/HtrA2 protease as a result of a missense mutation (Ser276Cys),
and invariably develop multiple organ defects including a neurodegen-
erative phenotype with parkinsonian features [15]. Furthermore, muta-
tions in Omi/HtrA2 have been reported in PD patients [18–20,60–62]
although other studies have contradicted those ﬁndings [63].
Omi/HtrA2's bacterial homologDegP is a known chaperone at normal
temperatures, and is used to remove denatured and unfolded proteins at
elevated temperatures [17,64,65]. Thus far, the function of Omi/HtrA2 in
the mitochondria has been deﬁned by its interaction with PINK and
rhomboid-7 proteins [17,66]. The function of this interaction was
proposed to be the post-translational modiﬁcation of Omi/HtrA2 and
the subsequent regulation of its protease activity [62,67]. In addition,
mitochondrial Omi/HtrA2 has been shown to cleave the anti-apoptotic
protein Hax-1, degrade Parkin, and associate with γ-secretase, Parl
(presenilin-associated, rhomboid-like), and mitochondrial fusion factor
OPA1 [21–25]. Under normal conditions, Omi/HtrA2 is found exclusively
in the IMS. Therefore,we investigatedwhether Omi/HtrA2 can potential-
ly regulate protein(s) that have a function in UPS but are also present in
the IMS. We identiﬁed the mitochondrial Mulan E3 ligase to be directly
controlled by Omi/HtrA2. The RING-ﬁnger domain of Mulan has amino
acid similarity with the corresponding domain of the Inhibitor of
Apoptosis Proteins (IAPs), which are known cytoplasmic substrates of
Omi/HtrA2 [28,68]. The biological signiﬁcance of this homology is
unclear. Our data indicate that the inter-membrane domain (IMD),
but not the cytoplasmic domain (CD) of Mulan can be degraded by
Omi/HtrA2 in vitro. Mulan protein levels are also regulated byOmi/HtrA2
in vivo and accumulate in MEFs that lack Omi/HtrA2. Accumulationof Mulan protein in Omi/HtrA2(−/−) MEFs can be prevented by ex-
pressing the wild type Omi/HtrA2, but not the mutant form of Omi/
HtrA2-S/A that lacks proteolytic activity. Of course, we cannot exclude
the possibility that Mulan is cleaved in vivo by a different protease that
is regulated in the presence of Omi/HtrA2. Deregulation of Mulan is
also seen in mnd2 mutant mice that lack an active Omi/HtrA2 protease,
resulting in Mulan protein accumulation in various tissues of these ani-
mals. The regulation of Mulan is speciﬁc; March5 and RNF185, the
other two known mitochondrial E3 ubiquitin ligases with similar topol-
ogy toMulan, are not affected by Omi/HtrA2 protease. Furthermore, dur-
ingH2O2Mulan is degraded and removed only in cells that have an active
Omi/HtrA2 protease. Since H2O2 causes the release of Omi/HtrA2 from
the mitochondria and induces cell death, we investigated whether deg-
radation of Mulan might be part of the pro-apoptotic function of Omi/
HtrA2 in the cytoplasm. Etoposide was used to induce cell death, which
is also associatedwith release of Omi/HtrA2 to the cytoplasm. In contrast
toH2O2, treatmentwith etoposide hadnodetectable effect on the level of
Mulan. These data strongly suggests that degradation ofMulan targets its
IMD and occurs while Omi/HtrA2 is conﬁned in themitochondria. In ad-
dition to etoposide, several other chemical treatments that induce cellu-
lar stress were used including cisplatin, antimycin, and paraquat. All
these treatments produced various levels of mitochondrial ROS and cell
death. None of them affected the level of Mulan protein. Mulan protein
levels had an inverse correlation with Mfn2 protein, a known substrate
of this E3 ligase that participates in mitochondrial fusion [30]. Whether
H2O2 regulates the activity of Omi/HtrA2 protease as seen by decreased
Mulan degradation is unknown. The effect of H2O2 on Omi/HtrA2 is
very speciﬁc and could not be reproduced using other chemical stressors.
H2O2 treatment of recombinant Omi/HtrA2 protein had no effect on the
enzyme's activity in vitro (Cilenti et al., unpublished). This result suggests
that H2O2 might act indirectly to affect Omi/HtrA2's activity in the
1305L. Cilenti et al. / Biochimica et Biophysica Acta 1843 (2014) 1295–1307mitochondria. Alternatively, H2O2 could act on the substrate– in this case
the IMD of Mulan – and by changing its conformationmake it more sus-
ceptible to proteolysis.We investigatedwhethermitophagymight be af-
fected in the absence of Omi/HtrA2 and the accumulation of Mulan. Our
experiments showed that Omi/HtrA2(+/+) MEFs have more healthy
mitochondria than Omi/HtrA2(−/−) or Omi/HtrA2-S/A cells. Increased
mitophagy/autophagy has also been reported in cells lacking active
Omi/HtrA2 protease [17]. In addition, up-regulation of Mulan through
transcriptional activation is known to increase mitophagy [30]. Omi/
HtrA2(−/−) MEFs showed increased mitophagy compared to wild
type Omi/HtrA2(+/+) cells. Mitophagy became more pronounced
when cells were treated with CCCP. Furthermore, Omi/HtrA2(−/−)
MEFs have more autophagosomes that co-localize with mitochondria
than Omi/HtrA2(+/+) cells, both under normal conditions and after
CCCP treatment. CCCP treatment inducedMulan protein that accumulat-
ed at much higher levels in Omi/HtrA2(−/−) or Omi/HtrA2-S/A than in
Omi/HtrA2(+/+) MEFs. Omi/HtrA2(−/−) MEFs contained a larger
number of autophagosomes and showed increased mitophagy than
Omi/HtrA2(+/+) cells. We further investigated whether the accumula-
tion of Mulan protein is actively involved in the process leading to in-
creased mitophagy in Omi/HtrA2(−/−) MEFs. We monitored the
protein level of Mfn2, a large GTPase and a known substrate of Mulan.
Mfn2 is essential for mitochondrial fusion and it is down-regulated dur-
ingmitophagy [69–71].Mulan directly ubiquitinatesMfn2,which targets
this protein for proteasomal degradation [30]. Conditional deletion of
Mfn2 in heart and skeletal muscles causes mitochondrial dysfunction,
cardiac hypertrophy, and muscle wasting [30,72,73]. Similar muscle
and heart phenotypes are also observed in mice lacking Omi/HtrA2 in
non-neuronal tissues [17]. Our results showed that the up-regulation of
Mulan, in the absence of Omi/HtrA2, leads to the degradation and re-
moval of Mfn2 in the heart of the mnd2 mice.
Our data clearly shows that Omi/HtrA2 regulates Mulan protein
levels and deregulation of this pathway leads to increased mitophagy.
It is also possible that this pathwaymight be involved in other biological
events besides mitophagy, or might have a different function in various
tissues. The function of Mulan in themitochondria under normal condi-
tions or during oxidative stress is unclear. Its unique topology allows the
protein to communicate signals from within mitochondria to the cyto-
plasm. Its regulation by Omi/HtrA2 suggests that the relative protein
levels of Mulan are important for its function. Our results showed that
its over-expression leads to degradation of Mfn2 and possibly other
substrates present in theOMMor the cytoplasm.Mfn2 is predominantly
expressed in the heart and skeletal muscles where it is probably the
main substrate of Mulan. Our recent studies suggest that Mulan can in-
teract with at least four different E2 ubiquitin conjugating enzymes, and
each unique Mulan/E2 complex can recognize different substrates
(Ambivero et al., in preparation).
In summary, we have identiﬁed a new mitochondrial pathway that
involves the regulation of Mulan E3 ubiquitin ligase by Omi/HtrA2 pro-
tease under normal conditions, after H2O2 exposure, or during CCCP
treatment. Inactivation of Omi/HtrA2 protease mimics mitochondrial
uncoupling since both lead to accumulation of Mulan. Mitochondrial
uncoupling has been previously implicated in the neurodegeneration
observed in the Omi/HtrA2 KO mice [74]. Mulan, like Parkin, is an
E3 ubiquitin ligase, but the role of Parkin in mitophagy has been exten-
sively studied [75]. There are also reports of Parkin-independent
mitophagy though themechanism remainsunknown [76]. The pathway
described here involving Mulan and its regulation by Omi/HtrA2 could
be an alternative mechanism to Parkin-induced mitophagy. In support
of this notion, loss of Omi/HtrA2 has been shown to have no affect on
the Parkin/Pink pathway [77]. In another study, Drosophila Omi/HtrA2
was found to act downstream of Pink1 and independently of Parkin
[78]. We expect that the accumulation of Mulan in the absence of
Omi/HtrA2 mimics mitochondrial uncoupling and activates mitophagy
of healthy mitochondria. This causes an imbalance in mitochondrial
numbers and affects primarily cells with high-energy requirements,such as neurons, cardiomyocytes, and muscle cells which begin to die.
We expect that this process is responsible for the phenotype observed
in the mnd2 mutant mice, which includes neurodegeneration, and a
plethora of other defects such as dilated cardiomyopathy andmuscle at-
rophy. It would be of interest to investigate whether mutations in
Mulan E3 ubiquitin ligase could be found in patients with neurodegen-
erative disorders or cardiomyopathies.
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